In 2000, Atsumi et al. pointed out that aPS/PT can be used not only to confirm the presence of LA, but also to serve (in addition to aCL and anti-β2GPI) as one of the markers of APS and also thrombotic events in patients with autoimmune diseases [7]. Here, ACLY is linked to autoimmune disease.